• CRO M&A Market in 2020 (So Far)

    There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For... Read More »
  • Ophthalmology Groups Are Still Selling

    Despite the effects of COVID-19 on physician groups, investors are still acquiring ophthalmology groups, especially in the third quarter, according to DSO. Just last week, EyeSouth Partners acquired Retina Associates of Middle Georgia (RAMG) for an undisclosed sum. Based in Macon, Georgia, RAMG provides treatment for the retina, macula, and... Read More »
  • Hospice M&A Activity Surges in 2020

    Despite the volatile market conditions for healthcare M&A, hospice targets have remained a remarkably consistent draw for investors, according to data captured in DSO. In the second quarter of 2020, 70% of HH&H transactions were for hospice specific targets, or targets that provided only hospice services, instead of a mix of hospice and... Read More »
  • Teladoc Health and Livongo Health Merge

    The virtual care giant Teladoc Health, Inc. (NYSE: TDOC) is having a wild year. The company’s second-quarter earnings reports showed Teladoc’s year-over-year revenues surged by 85% to $241 million, and its total telehealth visits rose to 2.8 million, a year-over-year increase of 203%, all thanks to the effects of COVD-19. And now,... Read More »
  • Health Care M&A Deals, August 7, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was... Read More »
Deal of the Week: McKesson/RxCrossroads

Deal of the Week: McKesson/RxCrossroads

The largest deal announced in a very sluggish week for healthcare announcements was McKesson Corp.’s (NYSE: MCK) $735 million acquisition of RxCrossroads from CVS Health Corp. (NYSE: CVS). RxCrossroads provides a range of specialty distribution, pharmacy and patient support to biopharmaceutical manufacturers. CVS acquired it in 2015 as part of its $12.7 billion deal for Omnicare Inc., which specialized in managing pharmaceutical care in long-term care and assisted living facilities. Omnicare paid $235 million for RxCrossroads in 2005, when it reported annualized revenue of $46 million. For McKesson, RxCrossroads will help it to capitalize on what the coming boom in the specialty... Read More »

Second Quarter Health Care M&A Spending Tanks

It’s still early yet, but we can say with confidence that the second quarter of 2015 doesn’t hold a candle to last year’s second quarter, at least dollar-wise. Last year, deal volume and value hit all-time highs for all previous Q2s, coming in at 325 deals and $135.8 billion in spending on those deals. This year, deal volume was fairly steady at 312 (remember, these are preliminary figures for Q2:15) but deal value plummeted 60% to $54.2 billion. We’ll have more details in the July issue of Health Care M&A News, but in the meantime, here are the biggest deals of Q2:15.  Read More »

Five Biggest Healthcare Deals in May 2015

The last week of May slowed to a crawl as far as announced health care transactions, but preliminary totals for deal volume and value indicate that May 2015 wasn’t too shabby. As of May 29, we counted 101 healthcare transactions, with a combined total of $32.4 billion. A year ago, there were 109 M&A announcements, for a total of $27.5 billion. We’ll go into detail in the June issue of Health Care M&A News, so watch for the publication announcement later this week.  Read More »

CVS Wins Omnicare Auction

Omnicare Inc. (NYSE: OCR) put itself on the market in April, with bids due in May. At the time, its market value was estimated to be about $8.5 billion. CVS Health Corp. (NYSE: CVS), Express Scripts Holding Co. (NASDAQ: ESRX), McKesson Corp. (NYSE: MCK) and Walgreens Boots Alliance Inc. (NASDAQ: WBA) were expected to kick the tires. Last week, CVS won the deal with $12.7 billion, including $2.3 billion in debt. Omnicare’s big draw is its specialty pharmaceutical business focused on assisted living and long-term care facilities. The deal follows UnitedHealth Group’s (NYSE: UNH) $12.8 billion acquisition of pharmacy benefits manager Catamaran Corp. (NASDAQ: CTRX) in March and Rite Aid... Read More »